Summary
Recent months have seen surges of SARS-CoV-2 infection across the globe along with considerable viral evolution1-3. Extensive mutations in the spike protein may threaten efficacy of vaccines and therapeutic monoclonal antibodies4. Two signature mutations of concern are E484K, which plays a crucial role in the loss of neutralizing activity of antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here, we report the emergence of a novel variant lineage B.1.526 that contains E484K and its alarming rise to dominance in New York City in recent months. This variant is partially or completely resistant to two therapeutic monoclonal antibodies in clinical use. It is also less susceptible to neutralization by convalescent plasma or vaccinee sera by 4.1-fold or 3.3-3.6-fold, respectively. The B.1.526 lineage has now been reported from at least 32 states in the US and numerous other countries. B.1526 has been outpacing B.1.1.7 in Northern Manhattan, and both variants have been spreading throughout New York with comparable estimated doubling times. Such transmission dynamics, together with its resistance to therapeutic antibodies, would warrant B.1.526 as a SARS-CoV-2 variant of concern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Biospecimens utilized for this research were obtained from the Columbia University Biobank (CUB), supported by the Irving Institute for Clinical and Translational Research, home to Columbia University Clinical and Translational Science Award (CTSA) funded through Grant Number UL1TR001873. This work was in part funded by NIH/NIDA grant U01 DA053949 (ACU, MKA) and by support from Andrew & Peggy Cherng, Samuel Yin, Barbara Picower and the JBP Foundation, Brii Biosciences, Roger & David Wu, and the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Columbia University Institutional Review Board (protocol number AAAT0123).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The manuscript was updated with additional sequencing data, new phylogenetic approaches and growth dynamic calculations, and additional pseudovirus antibody neutralization data.
Data Availability
All SARS-CoV-2 genomes generated as part of this study have been submitted to GISAID under submitter ID mka2136.
